Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Should Japan Go Ahead with Off-Year Re-Pricing amid COVID-19 Outbreak? Chuikyo Members Want It Discussed
April 9, 2020
- PMDA to Accept Trial Notifications by Email amid Coronavirus Outbreak
April 9, 2020
- MHLW Staffer Infected with Novel Coronavirus
April 9, 2020
- Talks with Regulators Ongoing for Ferinject, Zeria Says after Skipping Listing 4 Times
April 9, 2020
- AMED Invites Research Projects for COVID-19 Vaccine Development from Mid-April
April 9, 2020
- World’s 1st Topical JAK Inhibitor Corectim, AbbVie’s Rinvoq, Bayer’s Nubeqa OK’ed for Listing on April 22
April 8, 2020
- Novartis Japan Chided over Flawed Zolgensma Data, Delayed Responses
April 8, 2020
- Japan Books 13.9 Billion Yen to Boost Avigan Stockpile, Abe Vows to Expand Access to Fujifilm Drug
April 8, 2020
- Carcinogen in On-Market Nizatidine Products Acceptable Levels: MHLW
April 6, 2020
- Companies Should Reward Consistent Compliance with Detailing Guidelines in Performance Evaluations: MHLW Study
April 6, 2020
- Japan Mulling Free Avigan Supplies to 30-or-So Countries for COVID-19
April 6, 2020
- MHLW Allows Online IRB Meetings for Coronavirus Trials
April 3, 2020
- Japan’s Stimulus Package Likely to Support API Manufacturing Repatriation, Vaccine/Drug Development
April 3, 2020
- Companies “May” Provide Information to Individual Patients at Their Request: MHLW
April 3, 2020
- Gilead-Sponsored Remdesivir Trial Expected to Start This Month: Minister
April 3, 2020
- PMDA Introduces 3 New Consultation Services
April 2, 2020
- PMDA Issues Q&A for Trial Implementations in Coronavirus Crisis
April 2, 2020
- Keidanren Calls for Review of Health Coverage for OTC-Like Drugs
April 2, 2020
- Japan’s Healthcare Would Collapse before “Overshoot,” Govt Panel Warns
April 2, 2020
- Japan Ruling Parties Call for Fund to Support Healthcare Delivery System
April 2, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…